Patients carrying at least one copy of the *22 allele may have increased exposure to imatinib as compared to patients with. the*1/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.